

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited

華 熙 生 物 科 技 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

CLARIFICATION ANNOUNCEMENT IN RELATION TO THE 2015 ANNUAL REPORT OF THE COMPANY

References are made to (i) the annual report of Bloomage BioTechnology Corporation Limited (the “**Company**”) for the year ended 31 December 2015 (the “**Annual Report**”); and (ii) the announcements of the Company dated 5 and 20 November 2015 (the “**Announcements**”) in relation to the issue of convertible bonds and subscription of shares under the general mandate (the “**Issue and Subscription**”). Unless otherwise defined, capitalised terms used herein shall bear the same meanings as those defined in the Annual Report.

The board of directors of the Company (the “**Board**”) wishes to provide the shareholders of the Company and potential investors additional information on the use of net proceeds raised from the Issue and Subscription as follows:

Use of Proceeds from the Issue and Subscription

As disclosed in the Annual Report and the Announcements, the net proceeds from the Issue and Subscription amounted to approximately HK\$652.7 million.

As set out in the Announcements, the Company intended to use the net proceeds from the Issue and Subscription for financing potential mergers and acquisitions, capital expenditures and for working capital and general corporate purposes. In the period between completion of the Issue and Subscription on 20 November 2015 and 31 December 2015, the Company conducted discussions with various parties for potential mergers and acquisitions, however, none of which materialized. As at 31

December 2015, approximately HK\$62.6 million of the net proceeds from the Issue and Subscription were used for working capital and general corporate purposes and approximately HK\$590.1 million from the Issue and Subscription remained unused.

Since completion of the Issue and Subscription, the Group has been actively seeking opportunities for mergers and acquisitions. Actual use of proceeds from the Issue and Subscription would depend on whether the Group is able to identify suitable acquisition targets. In the event that the Group is unable to identify any suitable acquisition targets in the near future, the Board will consider utilizing the remaining proceeds from the Issue and Subscription for working capital and general corporate purposes including repayment of bank loans.

The above additional information does not affect any other information contained in the Annual Report and the contents of the Annual Report remain unchanged.

By order of the Board
Bloomage BioTechnology Corporation Limited
Zhao Yan
Chairman

Hong Kong, 5 September 2016

As at the date of this announcement, the executive directors are Ms. Zhao Yan, Mr. Jin Xuekun, Mr. Gong Anmin and Ms. Wang Aihua; the non-executive director is Mr. Yau Wai Yan; the independent non-executive directors are Ms. Zhan Lili, Mr. Li Junhong and Mr. Xue Zhaofeng.